Viking Therapeutics completes enrollment in phase 3 obesity trial

March 26, 2026 7:05 AM

Viking Therapeutics Inc. (NASDAQ: VKTX) announced it has completed patient enrollment in its Phase 3 VANQUISH-2 clinical trial evaluating VK2735 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found